Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma

Lung cancer is the leading cause of cancer death in China and worldwide. An increasing annual incidence and 5-year overall survival (OS) rate lower than 20%[1,2] has been verified in recent years in which LUAD accounts for 80% of primary pulmonary tumors [3]. The health hazard and huge economical burden derived from LUAD promote the need for novel and efficient treatment based on chemotherapy and targeted therapy [4,5].